MICAFUNGIN
Total Payments
$61,510
Transactions
24
Doctors
7
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $61,510 | 24 | 7 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $61,453 | 22 | 99.9% |
| Education | $57.00 | 2 | 0.1% |
Payments by Type
Research
$61,453
22 transactions
General
$57.00
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Candida Blood Stream Infections Defining Attributable Mortality and Building Predictive Models for Mortality and Antifungal Resistance. | Astellas Pharma Global Development | $58,860 | 0 |
| A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis | Astellas Pharma Global Development | $1,297 | 5 |
| Exposure-Response Analysis of Micafungin in Neonatal Candidiasis Pooled analysis of two clinical trials | Astellas Pharma Global Development | $702.25 | 5 |
| A Phase 3 Study of Micafungin versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis Neonates 3 | Astellas Pharma Global Development | $594.25 | 5 |
Top Doctors Receiving Payments for MICAFUNGIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Saint Louis, MO | $58,860 | 2 |
| David Kaufman | Pediatrics | Charlottesville, VA | $518.60 | 4 |
| , M.D | Infectious Disease | New York, NY | $518.60 | 4 |
| , M.D | Pediatric Infectious Diseases | Orange, CA | $518.60 | 4 |
| , MD | Neonatal-Perinatal Medicine | Durham, NC | $518.60 | 4 |
| Danny Benjamin | — | Durham, NC | $518.60 | 4 |
| , MD | Internal Medicine | New York, NY | $28.50 | 1 |
| , M.D | Internal Medicine | New York, NY | $28.50 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $61,510
- Total Doctors 7
- Transactions 24
About MICAFUNGIN
MICAFUNGIN is a drug associated with $61,510 in payments to 7 healthcare providers, recorded across 24 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2018 to 2018. In 2018, $61,510 was paid across 24 transactions to 7 doctors.
The most common payment nature for MICAFUNGIN is "Unspecified" ($61,453, 99.9% of total).
MICAFUNGIN is associated with 4 research studies, including "Candida Blood Stream Infections Defining Attributable Mortality and Building Predictive Models for Mortality and Antifungal Resistance." ($58,860).